Base de dados : MEDLINE
Pesquisa : C17.800.257 [Categoria DeCS]
Referências encontradas : 5058 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 506 ir para página                         

  1 / 5058 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28456787
[Au] Autor:Hichert V; Scholl C; Steffens M; Paul T; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
[Ad] Endereço:Research Division, Federal Institute for Drugs and Medical Devices, Bonn, Germany.
[Ti] Título:Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash.
[So] Source:Oncotarget;8(21):35193-35204, 2017 May 23.
[Is] ISSN:1949-2553
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Epidermal growth factor receptor overexpression in human cancer can be effectively targeted by drugs acting as specific inhibitors of the receptor, like erlotinib, gefitinib, cetuximab and panitumumab. A common adverse effect is a typical papulopustular acneiform rash, whose occurrence and severity are positively correlated with overall survival in several cancer types. We studied molecules involved in epidermal growth factor receptor signaling which are quantifiable in plasma, with the aim of identifying biomarkers for the severity of rash. With a predictive value for the rash these biomarkers may also have a prognostic value for survival and disease outcome.The concentrations of amphiregulin, hepatocyte growth factor (HGF) and calcidiol were determined by specific enzyme-linked immunosorbent assays in plasma samples from 211 patients.We observed a significant inverse correlation between the plasma concentration of HGF and overall survival in patients with an inhibitor-induced rash (p-value = 0.0075; mean overall survival low HGF: 299 days, high HGF: 240 days) but not in patients without rash. The concentration of HGF was also significantly inversely correlated with severity of rash (p-value = 0.00124).High levels of HGF lead to increased signaling via its receptor MET, which can activate numerous pathways which are normally also activated by epidermal growth factor receptor. Increased HGF/MET signaling might compensate the inhibitory effect of epidermal growth factor receptor inhibitors in skin as well as tumor cells, leading to less severe skin rash and decreased efficacy of the anti-tumor therapy, rendering the plasma concentration of HGF a candidate for predictive biomarkers.
[Mh] Termos MeSH primário: Exantema/induzido quimicamente
Fator de Crescimento de Hepatócito/sangue
Neoplasias/sangue
Neoplasias/tratamento farmacológico
Inibidores de Proteínas Quinases/administração & dosagem
Proteínas Proto-Oncogênicas c-met/sangue
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Anfirregulina/sangue
Biomarcadores Tumorais/sangue
Calcifediol/sangue
Cetuximab/administração & dosagem
Cetuximab/efeitos adversos
Cloridrato de Erlotinib/administração & dosagem
Cloridrato de Erlotinib/efeitos adversos
Exantema/sangue
Feminino
Seres Humanos
Masculino
Meia-Idade
Neoplasias/genética
Neoplasias/metabolismo
Estudos Prospectivos
Inibidores de Proteínas Quinases/efeitos adversos
Quinazolinas/administração & dosagem
Quinazolinas/efeitos adversos
Receptor do Fator de Crescimento Epidérmico/antagonistas & inibidores
Receptor do Fator de Crescimento Epidérmico/genética
Transdução de Sinais/efeitos dos fármacos
Análise de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (AREG protein, human); 0 (Amphiregulin); 0 (Biomarkers, Tumor); 0 (HGF protein, human); 0 (Protein Kinase Inhibitors); 0 (Quinazolines); 67256-21-7 (Hepatocyte Growth Factor); DA87705X9K (Erlotinib Hydrochloride); EC 2.7.10.1 (EGFR protein, human); EC 2.7.10.1 (MET protein, human); EC 2.7.10.1 (Proto-Oncogene Proteins c-met); EC 2.7.10.1 (Receptor, Epidermal Growth Factor); P6YZ13C99Q (Calcifediol); PQX0D8J21J (Cetuximab); S65743JHBS (gefitinib)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170501
[St] Status:MEDLINE
[do] DOI:10.18632/oncotarget.17060


  2 / 5058 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29371179
[Au] Autor:Chin X; Chan DKL; Chong JH
[Ad] Endereço:KK Women's and Children's Hospital, Singapore chin.xinyi@singhealth.com.sg.
[Ti] Título:A rash that's more than skin deep.
[So] Source:BMJ;360:k8, 2018 01 25.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Exantema/diagnóstico
Dermatoses Faciais/diagnóstico
Lúpus Eritematoso Sistêmico/congênito
Púrpura/diagnóstico
[Mh] Termos MeSH secundário: Diagnóstico Diferencial
Exantema/congênito
Dermatoses Faciais/congênito
Feminino
Seres Humanos
Lactente
Lúpus Eritematoso Sistêmico/complicações
Lúpus Eritematoso Sistêmico/diagnóstico
Púrpura/congênito
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180127
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.k8


  3 / 5058 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29326283
[Au] Autor:Wells L; Mahil S
[Ad] Endereço:Paediatric department, Evelina Children's Hospital, London, UK lyndonbenjamin.wells@nhs.net.
[Ti] Título:Rash on extensor surfaces of a child.
[So] Source:BMJ;360:j5547, 2018 01 11.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Acrodermatite/virologia
Exantema/virologia
[Mh] Termos MeSH secundário: Nádegas/virologia
Pré-Escolar
Cotovelo/virologia
Face/virologia
Seres Humanos
Joelho/virologia
Masculino
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.j5547


  4 / 5058 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29414279
[Au] Autor:Sato T; Coler-Reilly ALG; Yagishita N; Araya N; Inoue E; Furuta R; Watanabe T; Uchimaru K; Matsuoka M; Matsumoto N; Hasegawa Y; Yamano Y
[Ad] Endereço:From the Department of Rare Diseases Research, Institute of Medical Science (T.S., A.L.G.C.-R., N.Y., N.A., Y.Y.), Medical Informatics (E.I.), and the Departments of Pharmacology (N.M.) and Neurology (Y.H.), St. Marianna University School of Medicine, and the Department of Advanced Medical Innovatio
[Ti] Título:Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy.
[So] Source:N Engl J Med;378(6):529-538, 2018 02 08.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Human T-lymphotropic virus type 1 (HTLV-1) causes the debilitating neuroinflammatory disease HTLV-1-associated myelopathy-tropical spastic paraparesis (HAM-TSP) as well as adult T-cell leukemia-lymphoma (ATLL). In patients with HAM-TSP, HTLV-1 infects mainly CCR4+ T cells and induces functional changes, ultimately causing chronic spinal cord inflammation. We evaluated mogamulizumab, a humanized anti-CCR4 monoclonal antibody that targets infected cells, in patients with HAM-TSP. METHODS: In this uncontrolled, phase 1-2a study, we assessed the safety, pharmacokinetics, and efficacy of mogamulizumab in patients with glucocorticoid-refractory HAM-TSP. In the phase 1 dose-escalation study, 21 patients received a single infusion of mogamulizumab (at doses of 0.003 mg per kilogram of body weight, 0.01 mg per kilogram, 0.03 mg per kilogram, 0.1 mg per kilogram, or 0.3 mg per kilogram) and were observed for 85 days. Of those patients, 19 continued on to the phase 2a study and received infusions, over a period of 24 weeks, of 0.003 mg per kilogram, 0.01 mg per kilogram, or 0.03 mg per kilogram at 8-week intervals or infusions of 0.1 mg per kilogram or 0.3 mg per kilogram at 12-week intervals. RESULTS: The side effects of mogamulizumab did not limit administration up to the maximum dose (0.3 mg per kilogram). The most frequent side effects were grade 1 or 2 rash (in 48% of the patients) and lymphopenia and leukopenia (each in 33%). The dose-dependent reduction in the proviral load in peripheral-blood mononuclear cells (decrease by day 15 of 64.9%; 95% confidence interval [CI], 51.7 to 78.1) and inflammatory markers in cerebrospinal fluid (decrease by day 29 of 37.3% [95% CI, 24.8 to 49.8] in the CXCL10 level and of 21.0% [95% CI, 10.7 to 31.4] in the neopterin level) was maintained with additional infusions throughout the phase 2a study. A reduction in spasticity was noted in 79% of the patients and a decrease in motor disability in 32%. CONCLUSIONS: Mogamulizumab decreased the number of HTLV-1-infected cells and the levels of inflammatory markers. Rash was the chief side effect. The effect of mogamulizumab on clinical HAM-TSP needs to be clarified in future studies. (Funded by the Japan Agency for Medical Research and Development and the Ministry of Health, Labor, and Welfare; UMIN trial number, UMIN000012655 .).
[Mh] Termos MeSH primário: Anticorpos Monoclonais Humanizados/administração & dosagem
Antineoplásicos/administração & dosagem
Vírus 1 Linfotrópico T Humano/isolamento & purificação
Paraparesia Espástica Tropical/tratamento farmacológico
Receptores CCR4/antagonistas & inibidores
[Mh] Termos MeSH secundário: Adulto
Idoso
Anticorpos Monoclonais Humanizados/efeitos adversos
Anticorpos Monoclonais Humanizados/farmacocinética
Antineoplásicos/efeitos adversos
Antineoplásicos/farmacocinética
Área Sob a Curva
Relação Dose-Resposta a Droga
Esquema de Medicação
Exantema/induzido quimicamente
Feminino
Seres Humanos
Masculino
Meia-Idade
Paraparesia Espástica Tropical/imunologia
Linfócitos T/imunologia
Carga Viral
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Monoclonal, Humanized); 0 (Antineoplastic Agents); 0 (Receptors, CCR4); YI437801BE (mogamulizumab)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180208
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMoa1704827


  5 / 5058 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29267278
[Au] Autor:Ricciardi MJ; Magnani DM; Grifoni A; Kwon YC; Gutman MJ; Grubaugh ND; Gangavarapu K; Sharkey M; Silveira CGT; Bailey VK; Pedreño-Lopez N; Gonzalez-Nieto L; Maxwell HS; Domingues A; Martins MA; Pham J; Weiskopf D; Altman J; Kallas EG; Andersen KG; Stevenson M; Lichtenberger P; Choe H; Whitehead SS; Sette A; Watkins DI
[Ad] Endereço:Department of Pathology, University of Miami Miller School of Medicine, Miami, FL, United States of America.
[Ti] Título:Ontogeny of the B- and T-cell response in a primary Zika virus infection of a dengue-naïve individual during the 2016 outbreak in Miami, FL.
[So] Source:PLoS Negl Trop Dis;11(12):e0006000, 2017 12.
[Is] ISSN:1935-2735
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Zika virus (ZIKV) is a mosquito-borne flavivirus of significant public health concern. In the summer of 2016, ZIKV was first detected in the contiguous United States. Here we present one of the first cases of a locally acquired ZIKV infection in a dengue-naïve individual. We collected blood from a female with a maculopapular rash at day (D) 5 and D7 post onset of symptoms (POS) and we continued weekly blood draws out to D148 POS. To establish the ontogeny of the immune response against ZIKV, lymphocytes and plasma were analyzed in a longitudinal fashion. The plasmablast response peaked at D7 POS (19.6% of CD19+ B-cells) and was undetectable by D15 POS. ZIKV-specific IgM was present at D5 POS, peaked between D15 and D21 POS, and subsequently decreased. The ZIKV-specific IgG response, however, was not detected until D15 POS and continued to increase after that. Interestingly, even though the patient had never been infected with dengue virus (DENV), cross-reactive IgM and IgG binding against each of the four DENV serotypes could be detected. The highest plasma neutralization activity against ZIKV peaked between D15 and D21 POS, and even though DENV binding antibodies were present in the plasma of the patient, there was neither neutralization nor antibody dependent enhancement (ADE) of DENV. Interestingly, ADE against ZIKV arose at D48 POS and continued until the end of the study. CD4+ and CD8+ T-cells recognized ZIKV-NS2A and ZIKV-E, respectively. The tetramer positive CD8+ T-cell response peaked at D21 POS with elevated levels persisting for months. In summary, this is the first study to establish the timing of the ontogeny of the immune response against ZIKV.
[Mh] Termos MeSH primário: Anticorpos Antivirais/sangue
Linfócitos T CD4-Positivos/imunologia
Linfócitos T CD8-Positivos/imunologia
Imunoglobulina G/sangue
Imunoglobulina M/sangue
Zika virus/imunologia
[Mh] Termos MeSH secundário: Adulto
Anticorpos Antivirais/imunologia
Reações Cruzadas/imunologia
Vírus da Dengue/imunologia
Surtos de Doenças
Exantema/virologia
Feminino
Florida
Seres Humanos
Imunoglobulina G/imunologia
Imunoglobulina M/imunologia
RNA Viral/genética
Proteínas do Envelope Viral/imunologia
Zika virus/genética
Infecção pelo Zika virus/imunologia
Infecção pelo Zika virus/virologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Viral); 0 (Immunoglobulin G); 0 (Immunoglobulin M); 0 (RNA, Viral); 0 (Viral Envelope Proteins)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180210
[Lr] Data última revisão:
180210
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pntd.0006000


  6 / 5058 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28460866
[Au] Autor:Lubomski M; Brown L; Markus R
[Ad] Endereço:Department of Neurology, St Vincent's Hospital, 390 Victoria St, Darlinghurst, NSW, 2010 Sydney, Australia; The University of Notre Dame Australia, School of Medicine, Sydney, 160 Oxford St, Darlinghurst, NSW, 2010 Sydney, Australia. Electronic address: michal.lubomski@nd.edu.au.
[Ti] Título:An unusual presentation of varicella zoster virus with acute cerebellitis and SIADH without a rash.
[So] Source:J Clin Neurosci;41:90-91, 2017 Jul.
[Is] ISSN:1532-2653
[Cp] País de publicação:Scotland
[La] Idioma:eng
[Ab] Resumo:We report a case of varicella-zoster virus (VZV) infection with acute cerebellitis and encephalitis with associated Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) in an elderly man presenting with acute cerebellar ataxia without antecedent rash. Cerebrospinal fluid examination (CSF) revealed a mononuclear pleocytosis, high protein, normal glucose, positive for VZV polymerase chain reaction (PCR). Early acyclovir treatment is beneficial for acute VZV cerebellitis. Clinicians should consider infectious Central Nervous System (CNS) causes for presentations of acute cerebellar ataxia in adult patients, particularly if there is an accompanying clouded sensorium.
[Mh] Termos MeSH primário: Encefalite por Varicela Zoster/diagnóstico
Síndrome de Secreção Inadequada de HAD/diagnóstico
[Mh] Termos MeSH secundário: Aciclovir/uso terapêutico
Idoso de 80 Anos ou mais
Antivirais/uso terapêutico
Cerebelo/patologia
Encefalite por Varicela Zoster/tratamento farmacológico
Exantema/diagnóstico
Seres Humanos
Masculino
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antiviral Agents); X4HES1O11F (Acyclovir)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180112
[Lr] Data última revisão:
180112
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  7 / 5058 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29202152
[Au] Autor:Nunn A; Sturek JM; Reuss JE; Rein MF; Heysell SK
[Ad] Endereço:Department of Pediatrics, Penn State Health Children's Hospital, Hershey, PA, USA.
[Ti] Título:Subacute loss of vision in one eye · rash on hands and feet · plaques with scaling on genitals · Dx?
[So] Source:J Fam Pract;66(12):E9-E11, 2017 Dec.
[Is] ISSN:1533-7294
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A 67-year-old man presented to the hospital with subacute loss of vision in his left eye. The visual changes began 2 weeks earlier, with a central area of visual loss that had since progressed to near complete vision loss in the left eye. Physical examination revealed patchy alopecia, a scaling and hyperkeratotic rash of his hands and feet, and blanching, erythematous plaques with associated scaling on the scrotum and glans penis. Ophthalmologic examination revealed 1/200 vision in his left eye with a large plaque occupying a substantial portion of the superior quadrant, smaller perifoveal plaques in both of his eyes, and a small infiltrate above the left optic nerve head. The patient also described fatigue, loss of taste, and an unintentional weight loss of 7 to 10 kg over the previous 6 months. He had seen his primary care provider 3 months prior for a burning sensation and scaling rash on his feet and hands, and was prescribed a topical steroid.
[Mh] Termos MeSH primário: Infecções por HIV/diagnóstico
Sífilis/diagnóstico
[Mh] Termos MeSH secundário: Idoso
Antibacterianos/uso terapêutico
Fármacos Anti-HIV/uso terapêutico
Biópsia
Coinfecção
Ciclopentolato/uso terapêutico
Diagnóstico Diferencial
Exantema/diagnóstico
Exantema/tratamento farmacológico
Glucocorticoides/uso terapêutico
Infecções por HIV/tratamento farmacológico
Seres Humanos
Masculino
Midriáticos/uso terapêutico
Penicilinas/uso terapêutico
Prednisolona/uso terapêutico
Sífilis/tratamento farmacológico
Transtornos da Visão/diagnóstico
Transtornos da Visão/tratamento farmacológico
[Pt] Tipo de publicação:CASE REPORTS
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Anti-HIV Agents); 0 (Glucocorticoids); 0 (Mydriatics); 0 (Penicillins); 9PHQ9Y1OLM (Prednisolone); I76F4SHP7J (Cyclopentolate)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171208
[Lr] Data última revisão:
171208
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171205
[St] Status:MEDLINE


  8 / 5058 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29069049
[Au] Autor:Gao Y; Wang C; Gao Y; Chen H; Peng B; Chen W; Ran X
[Ad] Endereço:aDiabetic Foot Center, Department of Endocrinology and Metabolism bDepartment of Pathology cDepartment of Pancreatic Surgery dDepartment of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
[Ti] Título:Glucagonoma syndrome with serous oligocystic adenoma: A rare case report.
[So] Source:Medicine (Baltimore);96(43):e8448, 2017 Oct.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Glucagonoma and pancreatic serous oligocystic adenoma (SOA) are rare neuroendocrine and exocrine tumors of the pancreas, respectively. The coexistence of glucagonoma syndrome (GS) and SOA is a rare clinical condition and has not yet been reported. Additionally, necrolytic migratory erythema (NME), a hallmark clinical sign of GS, is often misdiagnosed as other skin lesions by clinicians due to their lack of related knowledge, which delays diagnosis of GS and thus exacerbates the prognosis. PATIENT CONCERNS: A 50-year-old male patient was admitted to our department because he presented with diabetes mellitus and a recurrent ulcerated skin rash. Prior to the accurate diagnosis, the skin manifestation was considered to be diabetic dermopathy. DIAGNOSES: The patient's fasting serum glucagon level was up to 871.5 pg/mL. A biopsy of the pancreatic tumor revealed a pancreatic neuroendocrine tumor, and immunoperoxidase staining revealed glucagon-positive cells. In addition, the histological examination of the pancreatic cystic lesions showed typical features of SOA. INTERVENTIONS: The patient received a pancreaticoduodenal resection and radiofrequency ablation for the hepatic nodular lesion. OUTCOMES: One week after surgery, the glucagon concentration decreased to near normal levels. The cutaneous lesions spontaneously resolved within 4 weeks after surgery. LESSONS: Because almost all glucagonomas are malignant or have malignant potential, their early recognition and correct diagnosis are very important for a better prognosis, especially in cases with NME as the only manifestation during the development of glucagonomas. It is therefore imperative that clinicians recognize NME early to make an accurate diagnosis.
[Mh] Termos MeSH primário: Cistadenoma Seroso/etiologia
Complicações do Diabetes/complicações
Glucagonoma/etiologia
Eritema Migratório Necrolítico/etiologia
Neoplasias Pancreáticas/etiologia
[Mh] Termos MeSH secundário: Diabetes Mellitus/patologia
Exantema/etiologia
Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171123
[Lr] Data última revisão:
171123
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171026
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008448


  9 / 5058 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29069010
[Au] Autor:Liu Y; Qi M; Hou S; Shao L; Zhang J; Li Y; Liu Q
[Ad] Endereço:Department of Dermatovenereology, Tianjin Medical University General Hospital, Tianjin, China.
[Ti] Título:Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: A meta-analysis of 9 randomized controlled trials.
[So] Source:Medicine (Baltimore);96(43):e8345, 2017 Oct.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Vandetanib is a promising anticancer target agent for treating advanced carcinomas, such as non-small-cell lung cancer (NSCLC) and breast cancer. Rash is a frequently reported adverse event of vandetanib. We conducted this meta-analysis to determine the incidence rate and overall risks of all-grade and high-grade rash with vandetanib in NSCLC patients. METHODS: PubMed, Embase, Web of Science, American Society of Clinical Oncology, and Cochrane Library were systematically searched to identify studies with vandetanib and rash in NSCLC patients. Data were extracted to calculate the pooled incidence of all-grade and high-grade (grade ≥3) rash caused by vandetanib treatment. RESULTS: Nine randomized controlled trials involving 4893 patients met the inclusion criteria and were included in this meta-analysis. The overall incidence of all-grade and high-grade rash caused by vandetanib treatment was 46% (95% CI: 37.1%, 54.8%), and 3.2% (95% CI: 1.4%, 5.1%), respectively. The risk ratios (RR) of all-grade and high-grade rash for vandetanib treatment versus control treatment were 2.35 (95% CI: 1.20, 4.61; P < .001) and 4.68 (95% CI 1.42, 15.37; P < .001), respectively. Subgroup analysis suggested that the increased risk of all-grade rash was clear across all subgroups, including first-line/second-line therapy, phase 2/phase 3 trial, sample size 200, a dosage of 100 or 300 mg, and monotherapy/combination therapy. However, for the high-grade rash, vandetanib did not increase the risk of rash when it was used in first-line therapy, or in a phase II trial, or in a trial with sample size <200. CONCLUSIONS: This study suggests that vandetanib was associated with a significantly increased risk of rash. Therefore, early recognition and appropriate monitoring should be taken when NSCLC patients were treated with vandetanib.
[Mh] Termos MeSH primário: Carcinoma Pulmonar de Células não Pequenas
Carcinoma
Exantema
Neoplasias Inflamatórias Mamárias
Piperidinas
Quinazolinas
[Mh] Termos MeSH secundário: Antineoplásicos/administração & dosagem
Antineoplásicos/efeitos adversos
Carcinoma/tratamento farmacológico
Carcinoma/patologia
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico
Carcinoma Pulmonar de Células não Pequenas/patologia
Exantema/induzido quimicamente
Exantema/diagnóstico
Exantema/epidemiologia
Seres Humanos
Incidência
Neoplasias Inflamatórias Mamárias/tratamento farmacológico
Neoplasias Inflamatórias Mamárias/patologia
Estadiamento de Neoplasias
Piperidinas/administração & dosagem
Piperidinas/efeitos adversos
Quinazolinas/administração & dosagem
Quinazolinas/efeitos adversos
Ensaios Clínicos Controlados Aleatórios como Assunto
Índice de Gravidade de Doença
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Piperidines); 0 (Quinazolines); YO460OQ37K (N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171123
[Lr] Data última revisão:
171123
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171026
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008345


  10 / 5058 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29061856
[Au] Autor:Barton M; McKelvie B; Campigotto A; Mullowney T
[Ad] Endereço:Sections of Infectious Diseases (Barton), Paediatric Critical Care (McKelvie), and Respirology (Mullowney), Department of Paediatrics; Division of Microbiology (Campigotto), Department of Pathology and Laboratory Medicine, London Health Sciences Centre, Western University, London, Ont. mabartonf@uwo
[Ti] Título:Legionellosis following water birth in a hot tub in a Canadian neonate.
[So] Source:CMAJ;189(42):E1311-E1313, 2017 10 23.
[Is] ISSN:1488-2329
[Cp] País de publicação:Canada
[La] Idioma:eng
[Mh] Termos MeSH primário: Parto Obstétrico/métodos
Legionelose/diagnóstico
Pneumonia Bacteriana/diagnóstico
[Mh] Termos MeSH secundário: Antibacterianos/administração & dosagem
Canadá
Exantema/etiologia
Feminino
Febre/etiologia
Seres Humanos
Recém-Nascido
Legionella/efeitos dos fármacos
Legionella/isolamento & purificação
Legionelose/tratamento farmacológico
Parto
Pneumonia Bacteriana/terapia
Respiração Artificial
Síndrome do Desconforto Respiratório do Recém-Nascido/complicações
Síndrome do Desconforto Respiratório do Recém-Nascido/terapia
Tomografia Computadorizada por Raios X
Microbiologia da Água
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171025
[St] Status:MEDLINE
[do] DOI:10.1503/cmaj.170711



página 1 de 506 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde